Intravitreal Aflibercept for the Treatment of Treatment Resistant Macular Oedema secondary to Retinal Vein Occlusions

ACTRN12617001487303

Status	RECRUITING
Phase	Phase 4
Sponsor	A/Prof Andrew Chang
Enrollment	50 participants

Plain Language Summary

This study is for people who have a swelling in the back of the eye (macular oedema) caused by a blocked retinal vein, and who have not responded well to existing eye injection treatments. Researchers want to find out if switching to a different medication called aflibercept (Eylea) can reduce the swelling and improve vision.

You may be eligible if:
- You are aged 18 or older
- You have macular oedema caused by a blocked retinal vein (retinal vein occlusion)
- You have already received at least 4 anti-VEGF injections over 6 months with ongoing swelling
- Your vision in the affected eye is between 6/12 and 6/120

You may NOT be eligible if:
- You are pregnant or breastfeeding
- You are a pre-menopausal woman not using contraception
- You have had an eye injection in the study eye within the past 30 days
- You have had eye surgery in the past 2 months
- You have had a stroke or heart attack in the past 3 months
- You have uncontrolled diabetes (HbA1c above 12%) or very high blood pressure (above 180/110)
- Your vision loss is due to another cause such as macular degeneration

Talk to your doctor about whether this trial might be right for you.

Key Eligibility Criteria

Inclusion (6)

- •Ability to provide informed consent and complete study assessments
- •Age 18 years or older
- •Macular oedema involving central macula secondary to ischemic or non-ischemic BRVO in study eye
- •Best corrected baseline visual acuity between 20-73 letters on ETDRS chart (Snellen equivalent 6/12 to 6/120) in the study eye.
- •Presence of central oedema (intra-retinal or sub-retinal fluid) on SD-OCT after at least 4 anti-VEGF treatments within 6 months.

... and 1 more (see full listing online)

Exclusion (17)

- •Pregnancy or lactation.
- •Premenopausal women not using contraception.
- •Prior anti-VEGF injection in the study eye within 30 days of baseline.
- •Prior treatment with triamcinolone in the study eye within 3 months of baseline.
- •Intraocular surgery in the study eye within 2 months of baseline

... and 12 more (see full listing online)

Locations (1 total)

Sydney Retina Clinic & Day Surgery - Sydney, NSW, Australia